SMC1A and myelodysplastic syndrome: Targeted sequencing of 104 MDS/AML candidate genes in 944 MDS samples. 47 genes were recurrently mutated in MDS. 14 of these genes (including STAG2) could successfully predict survival-outcome risk groups. STAG2 and SMC1A mutations were significantly associated with adverse patient outcome.